AU2020264083A1 - Methods of tumor vaccination - Google Patents

Methods of tumor vaccination Download PDF

Info

Publication number
AU2020264083A1
AU2020264083A1 AU2020264083A AU2020264083A AU2020264083A1 AU 2020264083 A1 AU2020264083 A1 AU 2020264083A1 AU 2020264083 A AU2020264083 A AU 2020264083A AU 2020264083 A AU2020264083 A AU 2020264083A AU 2020264083 A1 AU2020264083 A1 AU 2020264083A1
Authority
AU
Australia
Prior art keywords
tumor
composition
antigen
subject
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020264083A
Other languages
English (en)
Inventor
Erik Hans MANTING
Satwinder Kaur SINGH
Vinod SOMMANDAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mendus BV
Original Assignee
Mendus BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/NL2019/050451 external-priority patent/WO2020017962A1/en
Application filed by Mendus BV filed Critical Mendus BV
Publication of AU2020264083A1 publication Critical patent/AU2020264083A1/en
Assigned to Mendus B.V. reassignment Mendus B.V. Amend patent request/document other than specification (104) Assignors: DCPRIME B.V.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2020264083A 2019-04-25 2020-04-24 Methods of tumor vaccination Abandoned AU2020264083A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP19170999.7 2019-04-25
EP19170999 2019-04-25
PCT/NL2019/050451 WO2020017962A1 (en) 2018-07-16 2019-07-16 A combination product for use in tumor vaccination.
AUPCT/NL2019/050451 2019-07-16
US202062961554P 2020-01-15 2020-01-15
US62/961,554 2020-01-15
PCT/IB2020/053898 WO2020217226A1 (en) 2019-04-25 2020-04-24 Methods of tumor vaccination

Publications (1)

Publication Number Publication Date
AU2020264083A1 true AU2020264083A1 (en) 2021-12-02

Family

ID=72941340

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020264083A Abandoned AU2020264083A1 (en) 2019-04-25 2020-04-24 Methods of tumor vaccination

Country Status (6)

Country Link
US (2) US11052144B2 (https=)
EP (1) EP3958894A1 (https=)
JP (1) JP2022530044A (https=)
AU (1) AU2020264083A1 (https=)
CA (1) CA3133410A1 (https=)
WO (1) WO2020217226A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
GB201919316D0 (en) * 2019-12-24 2020-02-05 Queens Univ Of Belfast Polymeric nanoparticles for enhanced cancer treatment
CN115916963A (zh) 2020-03-27 2023-04-04 门德斯有限公司 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途
EP4171617A1 (en) 2020-06-30 2023-05-03 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
CA3196677A1 (en) * 2020-11-05 2022-05-12 Erik Hans MANTING Use of tumor-independent antigens in immunotherapies
JP2024506249A (ja) * 2021-01-22 2024-02-13 メンドゥス・ベスローテン・フェンノートシャップ 腫瘍ワクチン接種の方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US5667786A (en) 1995-06-07 1997-09-16 Novavax, Inc. Method for treating tumors with a toxin
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
US6398748B1 (en) 1999-03-16 2002-06-04 Robert B. Wilson Splint bandage and method
AU7116800A (en) 1999-09-09 2001-04-10 American Express Travel Related Services Company, Inc. System and method for authenticating a web page
WO2001049317A2 (en) 2000-01-05 2001-07-12 Aventis Pasteur Limited Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen
US7118740B1 (en) * 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
PT1346059E (pt) 2000-11-29 2012-06-01 Pci Biotech As Internalização fotoquímica para distribuição de moléculas no citosol
EP1339862B1 (en) 2000-11-29 2014-01-08 PCI Biotech AS Photochemical internalization for virus-mediated molecule delivery into the cytosol
CA2439111A1 (en) 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
US20040057935A1 (en) 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
JP2006232761A (ja) 2005-02-25 2006-09-07 Osaka Univ 制癌剤
AU2006260240B2 (en) 2005-06-21 2012-03-15 The Research Foundation For Microbial Diseases Of Osaka University Therapeutic agent for cancer
US8476419B2 (en) 2007-09-14 2013-07-02 Vrije Universiteit Brussel Enhancing the T-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
WO2009127988A1 (en) 2008-04-16 2009-10-22 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
WO2009019320A2 (en) 2008-05-19 2009-02-12 Dcprime B.V. Method for inducing and accelerating cells
GB0914286D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Method
CN103179952B (zh) 2010-09-02 2015-06-03 斯克里普斯研究学院 基于纳米颗粒的肿瘤靶向药物递送
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
NL2009102C2 (en) 2012-07-02 2014-01-06 Dcprime B V Method for dc-loading.
EP2743344A1 (en) 2012-12-11 2014-06-18 DCPrime B.V. Therapeutic cancer vaccines derived from a novel dendritic cell line
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
US9974848B2 (en) * 2013-11-14 2018-05-22 Duke University Tetanus toxoid and CCL3 improve DC vaccines
BR112019001115A2 (pt) 2016-07-21 2019-06-25 Vac4All Pte Ltd proteínas de biofusão como vacinas anti-malária
WO2020017962A1 (en) 2018-07-16 2020-01-23 Dcprime B.V. A combination product for use in tumor vaccination.

Also Published As

Publication number Publication date
WO2020217226A1 (en) 2020-10-29
US11052144B2 (en) 2021-07-06
EP3958894A1 (en) 2022-03-02
US20200390876A1 (en) 2020-12-17
CA3133410A1 (en) 2020-10-29
JP2022530044A (ja) 2022-06-27
US20210401961A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
US11052144B2 (en) Methods of tumor vaccination
US11071778B2 (en) Combination product for use in tumor vaccination
JP6903120B2 (ja) アルファウイルスワクチン接種のための組成物及び方法
RU2631002C2 (ru) Слитые белки для применения в качестве иммуногенных усиливающих агентов для индуцирования антигенспецифического т-клеточного ответа
US12528839B2 (en) Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
DK1581174T3 (en) Yeast-based vaccines such as immunotherapy
CN120939216A (zh) 抗hpv和hpv相关的疾病的新疫苗
WO2023052600A1 (en) Methods and particles for modulating an immune response
JP2025526447A (ja) 抗原送達用組換え融合タンパク質およびその使用
WO2024018062A1 (en) Immunoconjugate
US11865170B2 (en) DNA vaccine for human papillomavirus and method for using the same
HK1248560A1 (zh) Dna-肽组合疫苗
Ko et al. Lipid nanoparticle encapsulated TLR3 agonist adjuvant elicits potent T cell immunity against cancer and viruses
WO2025246436A1 (en) Circular rna-based therapeutic vaccine for treating hpv positive cancer
KR102654464B1 (ko) 레오바이러스 기반 신규한 백신플랫폼 및 이의 용도
CN121518519A (zh) 多价猪圆环病毒疫苗
CN121513182A (zh) 一种基于蛋白笼-mRNA技术的炭疽－鼠疫二联疫苗及其制备方法与用途
CN114269792A (zh) 稳定的嵌合合成蛋白及其治疗用途
Zeng et al. Soluble Proteins Induce Strong CD8+ T Cell

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: MENDUS B.V.

Free format text: FORMER NAME(S): DCPRIME B.V.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application